A detailed history of Bio Impact Capital LLC transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Bio Impact Capital LLC holds 267,557 shares of NTLA stock, worth $3.26 Million. This represents 0.86% of its overall portfolio holdings.

Number of Shares
267,557
Previous 443,503 39.67%
Holding current value
$3.26 Million
Previous $9.93 Million 44.6%
% of portfolio
0.86%
Previous 1.59%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$19.72 - $27.36 $3.47 Million - $4.81 Million
-175,946 Reduced 39.67%
267,557 $5.5 Million
Q2 2024

Aug 14, 2024

BUY
$20.02 - $27.22 $218,318 - $296,834
10,905 Added 2.52%
443,503 $9.93 Million
Q1 2024

May 15, 2024

BUY
$23.82 - $32.8 $1.19 Million - $1.64 Million
50,000 Added 13.07%
432,598 $11.9 Million
Q4 2023

Feb 13, 2024

SELL
$23.16 - $32.34 $3.75 Million - $5.24 Million
-162,041 Reduced 29.75%
382,598 $11.7 Million
Q2 2023

Aug 14, 2023

SELL
$34.58 - $46.03 $962,015 - $1.28 Million
-27,820 Reduced 4.86%
544,639 $22.2 Million
Q1 2023

May 12, 2023

BUY
$33.3 - $44.82 $3.9 Million - $5.25 Million
117,221 Added 25.75%
572,459 $21.3 Million
Q4 2022

Feb 14, 2023

BUY
$33.21 - $62.69 $2.68 Million - $5.07 Million
80,829 Added 21.59%
455,238 $15.9 Million
Q3 2022

Nov 14, 2022

BUY
$53.92 - $71.7 $4.04 Million - $5.38 Million
75,000 Added 25.05%
374,409 $21 Million
Q2 2022

Aug 11, 2022

BUY
$38.49 - $76.21 $5.39 Million - $10.7 Million
140,000 Added 87.82%
299,409 $15.5 Million
Q1 2022

May 13, 2022

SELL
$58.27 - $118.99 $65,145 - $133,030
-1,118 Reduced 0.7%
159,409 $11.6 Million
Q4 2021

Feb 11, 2022

SELL
$100.76 - $138.36 $210,890 - $289,587
-2,093 Reduced 1.29%
160,527 $19 Million
Q3 2021

Nov 15, 2021

BUY
$132.37 - $176.78 $4.56 Million - $6.09 Million
34,458 Added 26.89%
162,620 $21.8 Million
Q4 2020

Feb 16, 2021

BUY
$18.83 - $63.53 $2.41 Million - $8.14 Million
128,162 New
128,162 $6.97 Million

Others Institutions Holding NTLA

About Intellia Therapeutics, Inc.


  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $926M
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Bio Impact Capital LLC Portfolio

Follow Bio Impact Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bio Impact Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Bio Impact Capital LLC with notifications on news.